Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by REBIERE, I
Right arrow Articles by GALY-EYRAUD, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by REBIERE, I
Right arrow Articles by GALY-EYRAUD, C
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 Oxford University Press

research-article

Estimation of the Risk of Aseptic Meningitis Associated with Mumps Vaccination, France, 1991–1993

I REBIERE* and C GALY-EYRAUD{dagger}

*Réseau National de Santé Publique 14 rue du Val d'Osne, 94415 Saint-Maurice cedex, France
{dagger}Laboratoires Pasteur Mérieux Sérums et Vaccins, Pharmacovigilance Department 1541 avenue Marcel Mérieux, 69280 Marcy-l'Etoile, France

BACKGROUND: Several published studies have recently shown a higher Incidence of aseptic meningitis associated with Urabe AM-9 vaccine strain than that estimated previously. In France, where all mumps vaccines produced and marketed contain the Urabe AM-9 vaccine strain, little was known about the incidence of these side effects although several surveillance systems exist.

METHODS: The capture-recapture method can be used to estimate the total number of cases of a disease when at least two independent data sources are available. Applying the capture-recapture method, data provided by the national network of hospital virology laboratories (EPIVIR) and by the Pharmacovigilance Department of the vaccine manufacturer (P.M.sv.) during a 3-year period between 1 January 1991 and 31 December 1993 have been used to obtain an estimate of the total number of aseptic meningitis cases associated with Urabe AM-9 vaccine.

RESULTS: The number of such aseptic meningitis cases was estimated at 116 (95% confidence interval [Cl]: 49–183). The risk of aseptic meningitis can thus be assessed as 1 case per 28 400 doses of Urabe AM-9 sold (95% confidence interval [Cl]: 1 case per 18 000–1 case per 67 200). The sensitivity of the systems was 21% for EPIVIR and 23% for P.M.sv. The low number of cases recorded by either system makes it difficult to test the statistical independence of the two systems by the calculation of the correlation coefficient of the sensitivity of the systems after stratification. However, the stratified data by age, by sex, by geographical zone and by type of vaccine show that the totals after stratification are not very different from the crude total.

CONCLUSIONS: The French Vaccination Committee has recommended promoting the practice of measles-mumps-rubella vaccination in order to limit the circulation of the wild virus and to prevent an epidemic in Insufficiently protected groups of the population, whilst awaiting vaccine containing the Jeryl-Lynn strain.

Keywords mumps vaccine, aseptic meningitis, adverse effect, capture-recapture method

Revised 1 April 1995


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Am J EpidemiolHome page
M. Ki, T. Park, S. G. Yi, J. K. Oh, and B. Choi
Risk Analysis of Aseptic Meningitis after Measles-Mumps-Rubella Vaccination in Korean Children by Using a Case-Crossover Design
Am. J. Epidemiol., January 15, 2003; 157(2): 158 - 165.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
M. D. Lockshin
Genome and Hormones: Gender Differences in Physiology: Invited Review: Sex ratio and rheumatic disease
J Appl Physiol, November 1, 2001; 91(5): 2366 - 2373.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.